Nirav N. Shah, MD, MSHP, on a BTK Degrader in Relapsed or Refractory CLL

September 09, 2025 By The ASCO Post Staff

Nirav N. Shah, MD, MSHP, of the Medical College of Wisconsin, presents results from a phase Ia study of bexobrutideg, a Bruton’s tyrosine kinase (BTK) degrader. The agent was tested in a heavily pretreated population of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and resulted in a response rate of over 80%. 

Related Content